Soft-Tissue Sarcoma Therapeutics
The sponsor’s clinical research activity centers on advanced soft-tissue sarcoma, with particular attention to leiomyosarcoma and malignant peripheral nerve sheath tumor. Its funded studies address treatment options for selected advanced sarcoma populations in need of new systemic approaches.
- Advanced soft-tissue sarcoma
- Leiomyosarcoma
- Malignant peripheral nerve sheath tumor
The sponsor’s work in this area is concentrated in Spain, with collaboration across multiple research sites supporting sarcoma-focused clinical investigation.
Combination Therapy in Sarcoma
Another key area of interest is the evaluation of selinexor in combination with gemcitabine for selected advanced sarcomas. This reflects a therapeutic focus on combination regimens for difficult-to-treat soft-tissue malignancies.
- Selinexor
- Gemcitabine
- Combination treatment
These studies are directed toward patients with advanced disease where systemic therapy remains a central clinical need.
Novel Anticancer Agents
The sponsor also supports research into cirtuvivint for selected advanced soft-tissue sarcomas, indicating interest in emerging anticancer agents for sarcoma management.
- Cirtuvivint
- Experimental sarcoma therapy
This area complements its broader focus on developing treatment options for advanced sarcoma subtypes.
